29 Other provisions continued Major restructuring programmes In October 2007 the Group announced the Operational Excellence programme to improve the effectiveness and productivity of its operations see Note 10, Major restructuring costs.
In addition, in 2013, the Group initiated the Major Change restructuring programme focused on opportunities to simplify supply chain processes, build the Groups capabilities in manufacturing and R&D and restructure the European Pharmaceuticals business.
Provisions for staff severance payments are made when management has made a formal decision to eliminate certain positions and this has been communicated to the groups of employees affected and appropriate consultation procedures completed, where appropriate.
No provision is made for staff severance payments that are made immediately.
Pension augmentations arising from staff redundancies of nil 2012 4 million have been charged during the year and then transferred to the pension obligations provision as shown in Note 28, Pensions and other post-employment benefits.
Asset write-downs have been recognised as impairments of property, plant and equipment in Note 17, Property, plant and equipment.
The majority of the amounts provided are expected to be utilised in the next two years.
Employee related provisions Employee related provisions include obligations for certain medical benefits to disabled employees and their spouses in the USA.
At 31 December 2013, the provision for these benefits amounted to 111 million 2012 113 million.
Other employee benefits reflect a variety of provisions for severance costs, jubilee awards and other long-service benefits.
Other provisions Included in other provisions are insurance provisions of 31 million 2012 29 million, onerous property lease provisions of 33 million 2012 16 million and a number of other provisions including vehicle insurance and regulatory matters.
30 Other non-current liabilities 2013 2012 m m Accruals and deferred income 101 73 Other payables 1,603 1,359 1,704 1,432 The increase in other payables primarily arises from contingent consideration of 253 million relating to the acquisition of the 50% share of the Shionogi-ViiV Healthcare joint venture previously held by Shionogi & Co Ltd in 2012.
